US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

24.88

-0.6200-2.43%

Volume:661.65K

Turnover:16.38M

Market Cap:3.21B

PE:-6.55

High:25.32

Open:25.26

Low:24.36

Close:25.50

52wk High:31.35

52wk Low:3.76

Shares:129.00M

Float Shares:87.09M

Volume Ratio:0.63

T/O Rate:0.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.8005

EPS(LYR):-2.8616

ROE:-93.65%

ROA:-45.34%

PB:7.10

PE(LYR):-8.69

Loading ...

Overview Company News Filings

What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders

Simply Wall St.

Alumis Publishes Corporate Deck on Next-Generation TYK2 Inhibitors for Immune-Mediated Diseases

Alumis Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)

Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)

Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate

Benzinga Earnings

Alumis Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Alumis Q2 FY26 Net Loss Widens to $142.22 Million; Revenue Falls 37.65% to $1.66 Million

Alumis - to Initiate Phase 2 Trial for A-005 in Parkinson's Disease in 1H 2027

THOMSON REUTERS

Alumis - on Track to Submit Nda for Envudeucitinib in Pso to FDA in Q4 2026

THOMSON REUTERS

Press Release: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

Alumis Inc. (ALMS) Receives a Rating Update from a Top Analyst

Alumis reports strong Phase 3 data for envudeucitinib

Alumis - Envudeucitinib Shows Consistent Safety Profile with no New Safety Signals in Onward3

THOMSON REUTERS

Alumis - Topline Data from Lumus Phase 2B Trial in Lupus Expected in Q3 2026

THOMSON REUTERS

Alumis - to Submit Nda to FDA for Envudeucitinib in Q4 2026

THOMSON REUTERS

Alumis - 75% of Patients Achieve Pasi 90, 54% Achieve Pasi 100 After 48 Weeks

THOMSON REUTERS

Alumis Says Envudeucitinib Hits 54% PASI 100 at 48 Weeks in Onward3 Plaque Psoriasis Extension Study

Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies

Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALMS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":24.88,"timestamp":1787083200000,"preClose":25.5,"halted":0,"volume":661654,"delay":0,"changeRate":-0.024313725490196118,"floatShares":87090293,"shares":129000000,"eps":-3.800544,"marketStatus":"Pre-Mkt","change":-0.62,"latestTime":"08-19 04:16:47 EDT","open":25.26,"high":25.32,"low":24.36,"amount":16382050.182959998,"amplitude":0.037647,"askPrice":28,"askSize":18,"bidPrice":21.18,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.800544,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787146200000},"marketStatusCode":1,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":24.88,"postHourTrading":{"tag":"盘后","latestPrice":24.88,"preClose":24.88,"latestTime":"19:30 EDT","volume":16227,"amount":403742.16,"timestamp":1787095806032,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.634964901216271,"impliedVol":1.9745,"impliedVolPercentile":0.92},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":87090293,"roa":"-45.34%","roe":"-93.65%","lyrEps":-2.861649,"volumeRatio":0.634964901216271,"shares":129000000,"dividePrice":0,"high":25.32,"amplitude":0.037647,"preClose":25.5,"low":24.36,"week52Low":3.76,"pbRate":"7.10","psRate":"433.84","week52High":31.35,"institutionHeld":0,"latestPrice":24.88,"committee":0.694915,"eps":-3.800544,"divideRate":0,"volume":661654,"delay":0,"ttmEps":-3.800544,"open":25.26,"prevYearClose":9.76,"prevWeekClose":25.31,"prevMonthClose":28.25,"prevQuarterClose":28.14,"fiveDayClose":25.37,"twentyDayClose":30.05,"sixtyDayClose":22.17},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-14","symbol":"ALMS","fiscalQuarterEnding":"2026/03","expectedEps":-0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2026-03-19","symbol":"ALMS","fiscalQuarterEnding":"2025/12","expectedEps":-0.97,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":-0.95},{"market":"US","date":"2025-11-13","symbol":"ALMS","fiscalQuarterEnding":"2025/09","expectedEps":-0.92,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2025-08-13","symbol":"ALMS","fiscalQuarterEnding":"2025/06","expectedEps":-1.11,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-1.17},{"market":"US","date":"2025-05-14","symbol":"ALMS","fiscalQuarterEnding":"2025/03","expectedEps":-1.47,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1747195200000,"reportTimeType":"post","actualEps":-1.82}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.3,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":10,"updateTime":1778904000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2026-08-17","current":-6.546431,"percent":0.280374,"low":-16.271116,"twenty":-12.351012,"median":-3.072226,"eighty":-1.162092,"high":-0.443678,"avg":-5.259253,"sd":5.081271,"marketCap":3276005899},"quantilePoints":[{"date":"2024-06-28","current":-4.084559,"twenty":-4.913756,"median":-4.913756,"eighty":-4.416238,"marketCap":689534895},{"date":"2024-07-05","current":-3.516406,"twenty":-4.747917,"median":-3.851156,"eighty":-3.59564,"marketCap":593622147},{"date":"2024-07-12","current":-3.405847,"twenty":-4.063676,"median":-3.825051,"eighty":-3.58397,"marketCap":574958044},{"date":"2024-07-19","current":-4.023985,"twenty":-4.026561,"median":-3.851156,"eighty":-3.52869,"marketCap":679309112},{"date":"2024-07-26","current":-4.023985,"twenty":-4.117224,"median":-3.947896,"eighty":-3.58397,"marketCap":679309112},{"date":"2024-08-02","current":-4.178507,"twenty":-4.123137,"median":-3.980142,"eighty":-3.620209,"marketCap":705394582},{"date":"2024-08-09","current":-3.850149,"twenty":-4.108328,"median":-3.938677,"eighty":-3.693301,"marketCap":649962958},{"date":"2024-08-16","current":-3.683794,"twenty":-4.085032,"median":-3.914533,"eighty":-3.659692,"marketCap":696362265},{"date":"2024-08-23","current":-3.672282,"twenty":-4.078883,"median":-3.855481,"eighty":-3.667968,"marketCap":694186133},{"date":"2024-08-30","current":-3.655014,"twenty":-4.050383,"median":-3.84693,"eighty":-3.659692,"marketCap":690921935},{"date":"2024-09-06","current":-3.442045,"twenty":-4.027205,"median":-3.798947,"eighty":-3.608967,"marketCap":650663491},{"date":"2024-09-13","current":-3.33556,"twenty":-4.023985,"median":-3.741353,"eighty":-3.511116,"marketCap":630534270},{"date":"2024-09-20","current":-3.301025,"twenty":-4.023985,"median":-3.709695,"eighty":-3.405847,"marketCap":624005873},{"date":"2024-09-27","current":-3.211808,"twenty":-3.980142,"median":-3.685233,"eighty":-3.395997,"marketCap":607140850},{"date":"2024-10-04","current":-2.803137,"twenty":-3.959602,"median":-3.672282,"eighty":-3.303903,"marketCap":529888161},{"date":"2024-10-11","current":-2.978693,"twenty":-3.946725,"median":-3.656453,"eighty":-3.263611,"marketCap":563074175},{"date":"2024-10-18","current":-3.462191,"twenty":-3.930629,"median":-3.608967,"eighty":-3.220442,"marketCap":654471723},{"date":"2024-10-25","current":-3.424777,"twenty":-3.915649,"median":-3.608753,"eighty":-3.22332,"marketCap":647399293},{"date":"2024-11-01","current":-3.254977,"twenty":-3.914533,"median":-3.516406,"eighty":-3.231953,"marketCap":615301345},{"date":"2024-11-08","current":-3.459313,"twenty":-3.86344,"median":-3.50536,"eighty":-3.240587,"marketCap":653927690},{"date":"2024-11-15","current":-2.016571,"twenty":-3.859807,"median":-3.465068,"eighty":-3.22332,"marketCap":481504843},{"date":"2024-11-22","current":-2.155567,"twenty":-3.851156,"median":-3.454996,"eighty":-3.18015,"marketCap":514693313},{"date":"2024-11-29","current":-2.109995,"twenty":-3.85035,"median":-3.444923,"eighty":-3.067334,"marketCap":503811848},{"date":"2024-12-06","current":-2.050751,"twenty":-3.847574,"median":-3.439167,"eighty":-2.978693,"marketCap":489665943},{"date":"2024-12-13","current":-1.911755,"twenty":-3.823752,"median":-3.419021,"eighty":-2.94646,"marketCap":456477473},{"date":"2024-12-20","current":-2.009736,"twenty":-3.802749,"median":-3.405847,"eighty":-2.329653,"marketCap":479872624},{"date":"2024-12-27","current":-1.836561,"twenty":-3.764391,"median":-3.395997,"eighty":-2.153744,"marketCap":438523055},{"date":"2025-01-03","current":-1.925427,"twenty":-3.741353,"median":-3.367218,"eighty":-2.142807,"marketCap":459741913},{"date":"2025-01-10","current":-1.595028,"twenty":-3.741353,"median":-3.312536,"eighty":-2.023407,"marketCap":380851289},{"date":"2025-01-17","current":-1.745417,"twenty":-3.740777,"median":-3.298147,"eighty":-1.989684,"marketCap":416760124},{"date":"2025-01-24","current":-1.522113,"twenty":-3.738475,"median":-3.27944,"eighty":-1.964163,"marketCap":363440944},{"date":"2025-01-31","current":-1.704402,"twenty":-3.735597,"median":-3.263611,"eighty":-1.93682,"marketCap":406966805},{"date":"2025-02-07","current":-1.291973,"twenty":-3.709695,"median":-3.247782,"eighty":-1.911755,"marketCap":308489544},{"date":"2025-02-14","current":-1.187157,"twenty":-3.703939,"median":-3.22332,"eighty":-1.873019,"marketCap":283462173},{"date":"2025-02-21","current":-1.178042,"twenty":-3.690125,"median":-3.211808,"eighty":-1.829725,"marketCap":281285880},{"date":"2025-02-28","current":-1.059555,"twenty":-3.68437,"median":-3.162882,"eighty":-1.759544,"marketCap":252994070},{"date":"2025-03-07","current":-1.111963,"twenty":-3.676887,"median":-3.070787,"eighty":-1.711693,"marketCap":265507755},{"date":"2025-03-14","current":-1.041326,"twenty":-3.672858,"median":-3.006033,"eighty":-1.678881,"marketCap":248641484},{"date":"2025-03-21","current":-0.693421,"twenty":-3.667968,"median":-2.978693,"eighty":-1.565406,"marketCap":204027476},{"date":"2025-03-28","current":-1.042906,"twenty":-3.659692,"median":-2.965742,"eighty":-1.505251,"marketCap":306857324},{"date":"2025-04-04","current":-1.85837,"twenty":-3.65559,"median":-2.803137,"eighty":-1.500694,"marketCap":546793636},{"date":"2025-04-11","current":-1.198232,"twenty":-3.63199,"median":-2.286587,"eighty":-1.463027,"marketCap":352559478},{"date":"2025-04-17","current":-0.924562,"twenty":-3.622781,"median":-2.176074,"eighty":-1.280365,"marketCap":272036635},{"date":"2025-04-25","current":-0.791425,"twenty":-3.613572,"median":-2.146452,"eighty":-1.183511,"marketCap":232863359},{"date":"2025-05-02","current":-0.848748,"twenty":-3.60871,"median":-2.125945,"eighty":-1.162092,"marketCap":249729630},{"date":"2025-05-09","current":-0.930109,"twenty":-3.590112,"median":-2.016571,"eighty":-1.140673,"marketCap":273668854},{"date":"2025-05-16","current":-0.890525,"twenty":-3.561975,"median":-1.997203,"eighty":-1.105127,"marketCap":305759157},{"date":"2025-05-23","current":-0.766929,"twenty":-3.530406,"median":-1.968721,"eighty":-1.070948,"marketCap":263322832},{"date":"2025-05-30","current":-0.619565,"twenty":-3.51429,"median":-1.964163,"eighty":-1.045883,"marketCap":212725677},{"date":"2025-06-06","current":-0.530829,"twenty":-3.506511,"median":-1.95277,"eighty":-1.037224,"marketCap":182258572},{"date":"2025-06-13","current":-0.503891,"twenty":-3.48667,"median":-1.925427,"eighty":-0.984896,"marketCap":173009629},{"date":"2025-06-20","current":-0.476954,"twenty":-3.466829,"median":-1.916313,"eighty":-0.943233,"marketCap":163760687},{"date":"2025-06-27","current":-0.522906,"twenty":-3.464493,"median":-1.909477,"eighty":-0.920124,"marketCap":179538295},{"date":"2025-07-03","current":-0.538752,"twenty":-3.462191,"median":-1.878715,"eighty":-0.88573,"marketCap":184978849},{"date":"2025-07-11","current":-0.564105,"twenty":-3.459313,"median":-1.85837,"eighty":-0.848748,"marketCap":193683736},{"date":"2025-07-18","current":-0.556182,"twenty":-3.450679,"median":-1.833144,"eighty":-0.808067,"marketCap":190963459},{"date":"2025-07-25","current":-0.611642,"twenty":-3.444923,"median":-1.819538,"eighty":-0.791425,"marketCap":210005399},{"date":"2025-08-01","current":-0.65601,"twenty":-3.444923,"median":-1.768203,"eighty":-0.766929,"marketCap":225238952},{"date":"2025-08-08","current":-1.301335,"twenty":-3.442045,"median":-1.745417,"eighty":-0.761839,"marketCap":446809517},{"date":"2025-08-15","current":-2.007939,"twenty":-3.439167,"median":-1.743138,"eighty":-0.765537,"marketCap":456842285},{"date":"2025-08-22","current":-2.103991,"twenty":-3.427655,"median":-1.761367,"eighty":-0.766929,"marketCap":478695789},{"date":"2025-08-29","current":-2.14973,"twenty":-3.424777,"median":-1.805264,"eighty":-0.766929,"marketCap":489102219},{"date":"2025-09-05","current":-2.103991,"twenty":-3.415567,"median":-1.826307,"eighty":-0.771366,"marketCap":478695789},{"date":"2025-09-12","current":-1.994217,"twenty":-3.40866,"median":-1.836561,"eighty":-0.773109,"marketCap":453720356},{"date":"2025-09-19","current":-1.9622,"twenty":-3.406179,"median":-1.867544,"eighty":-0.787793,"marketCap":446435855},{"date":"2025-09-26","current":-1.824983,"twenty":-3.405847,"median":-1.875296,"eighty":-0.795863,"marketCap":415216564},{"date":"2025-10-03","current":-1.811262,"twenty":-3.397967,"median":-1.860219,"eighty":-0.799931,"marketCap":412094635},{"date":"2025-10-10","current":-2.071974,"twenty":-3.391392,"median":-1.873019,"eighty":-0.803629,"marketCap":471411288},{"date":"2025-10-17","current":-2.108565,"twenty":-3.371823,"median":-1.884428,"eighty":-0.807327,"marketCap":479736432},{"date":"2025-10-24","current":-2.108565,"twenty":-3.341892,"median":-1.893592,"eighty":-0.812505,"marketCap":479736432},{"date":"2025-10-31","current":-2.131434,"twenty":-3.317141,"median":-1.904969,"eighty":-0.82249,"marketCap":484939647},{"date":"2025-11-07","current":-2.158878,"twenty":-3.30563,"median":-1.911755,"eighty":-0.843135,"marketCap":491183505},{"date":"2025-11-14","current":-2.422653,"twenty":-3.301601,"median":-1.918592,"eighty":-0.848547,"marketCap":551197167},{"date":"2025-11-21","current":-2.946741,"twenty":-3.29642,"median":-1.93682,"eighty":-0.86502,"marketCap":722402348},{"date":"2025-11-28","current":-3.266113,"twenty":-3.290089,"median":-1.953052,"eighty":-0.869088,"marketCap":800697401},{"date":"2025-12-05","current":-3.534386,"twenty":-3.297571,"median":-1.962042,"eighty":-0.870197,"marketCap":866465244},{"date":"2025-12-12","current":-4.943882,"twenty":-3.336738,"median":-1.966442,"eighty":-0.879813,"marketCap":1212007408},{"date":"2025-12-19","current":-4.709675,"twenty":-3.399937,"median":-1.972322,"eighty":-0.888607,"marketCap":1154591037},{"date":"2025-12-26","current":-4.854457,"twenty":-3.410963,"median":-1.990368,"eighty":-0.898223,"marketCap":1190084794},{"date":"2026-01-02","current":-4.156097,"twenty":-3.436865,"median":-1.996504,"eighty":-0.911618,"marketCap":1018879613},{"date":"2026-01-09","current":-7.741582,"twenty":-3.449528,"median":-2.003365,"eighty":-0.920124,"marketCap":1897872066},{"date":"2026-01-16","current":-12.290084,"twenty":-3.466829,"median":-2.013154,"eighty":-0.925671,"marketCap":3012950964},{"date":"2026-01-23","current":-13.362987,"twenty":-3.516406,"median":-2.019374,"eighty":-0.930109,"marketCap":3275976472},{"date":"2026-01-30","current":-13.647739,"twenty":-3.577828,"median":-2.030809,"eighty":-0.937506,"marketCap":3345784190},{"date":"2026-02-06","current":-13.393497,"twenty":-3.626234,"median":-2.053678,"eighty":-0.942816,"marketCap":3283455871},{"date":"2026-02-13","current":-13.6274,"twenty":-3.672282,"median":-2.062826,"eighty":-0.944902,"marketCap":3340797925},{"date":"2026-02-20","current":-14.850306,"twenty":-3.690125,"median":-2.071974,"eighty":-0.965612,"marketCap":3640597141},{"date":"2026-02-27","current":-15.244382,"twenty":-3.739051,"median":-2.087982,"eighty":-0.981145,"marketCap":3737206037},{"date":"2026-03-06","current":-14.054527,"twenty":-3.801818,"median":-2.103991,"eighty":-0.986058,"marketCap":3445509501},{"date":"2026-03-13","current":-12.727381,"twenty":-3.85035,"median":-2.108565,"eighty":-0.99467,"marketCap":3120155674},{"date":"2026-03-20","current":-13.002303,"twenty":-3.914756,"median":-2.117713,"eighty":-1.01599,"marketCap":3163785497},{"date":"2026-03-27","current":-13.758909,"twenty":-3.96371,"median":-2.12686,"eighty":-1.031756,"marketCap":3347886444},{"date":"2026-04-02","current":-11.882219,"twenty":-4.025273,"median":-2.141239,"eighty":-1.038592,"marketCap":2891240839},{"date":"2026-04-10","current":-11.991997,"twenty":-4.096739,"median":-2.146452,"eighty":-1.041326,"marketCap":2917952699},{"date":"2026-04-17","current":-13.068872,"twenty":-4.165061,"median":-2.15037,"eighty":-1.042274,"marketCap":3179983325},{"date":"2026-04-24","current":-13.5864,"twenty":-4.472062,"median":-2.155567,"eighty":-1.044692,"marketCap":3305910664},{"date":"2026-05-01","current":-12.906818,"twenty":-4.742038,"median":-2.161164,"eighty":-1.045883,"marketCap":3140551531},{"date":"2026-05-08","current":-12.420656,"twenty":-4.831463,"median":-2.172599,"eighty":-1.054086,"marketCap":3022256152},{"date":"2026-05-15","current":-13.226323,"twenty":-4.877452,"median":-2.191451,"eighty":-1.062289,"marketCap":3140127467},{"date":"2026-05-22","current":-11.905302,"twenty":-5.029048,"median":-2.200043,"eighty":-1.070948,"marketCap":2826497196},{"date":"2026-05-29","current":-11.491811,"twenty":-7.697296,"median":-2.214811,"eighty":-1.081885,"marketCap":2728328372},{"date":"2026-06-05","current":-10.949441,"twenty":-10.746475,"median":-2.229773,"eighty":-1.094189,"marketCap":2599561472},{"date":"2026-06-12","current":-11.223311,"twenty":-10.767935,"median":-2.309816,"eighty":-1.101025,"marketCap":2664582382},{"date":"2026-06-18","current":-12.377862,"twenty":-10.942997,"median":-2.358363,"eighty":-1.105127,"marketCap":2938690139},{"date":"2026-06-26","current":-13.441123,"twenty":-11.434889,"median":-2.409687,"eighty":-1.106494,"marketCap":3191124259},{"date":"2026-07-02","current":-14.305694,"twenty":-11.51629,"median":-2.443671,"eighty":-1.111963,"marketCap":3396386347},{"date":"2026-07-10","current":-16.271116,"twenty":-11.77244,"median":-2.7977,"eighty":-1.135362,"marketCap":3863006994},{"date":"2026-07-17","current":-14.622524,"twenty":-11.882219,"median":-2.91667,"eighty":-1.139306,"marketCap":3471606615},{"date":"2026-07-24","current":-15.197115,"twenty":-11.985852,"median":-2.970059,"eighty":-1.141585,"marketCap":3608023034},{"date":"2026-07-31","current":-15.546165,"twenty":-12.051591,"median":-2.978693,"eighty":-1.145231,"marketCap":3690892821},{"date":"2026-08-07","current":-14.928615,"twenty":-12.229666,"median":-3.006033,"eighty":-1.151611,"marketCap":3544277044},{"date":"2026-08-14","current":-13.30798,"twenty":-12.354486,"median":-3.070787,"eighty":-1.160269,"marketCap":3159514183},{"date":"2026-08-17","current":-7.463159,"twenty":-12.351012,"median":-3.072226,"eighty":-1.162092,"marketCap":3276005899}],"updateTime":1787114921053},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660041619","title":"What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2660041619","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660041619?lang=en_us&edition=fundamental","pubTime":"2026-08-19 09:22","pubTimestamp":1787102572,"startTime":"0","endTime":"0","summary":"Earlier in August 2026, Alumis Inc. reported second-quarter results showing revenue of US$1.66 million and a net loss of US$142.22 million, reversing a net profit a year earlier as loss per share widened sharply.\nA few days before that earnings release, Alumis reported positive topline Phase 3 ONWARD3 extension data for its oral TYK2 inhibitor envudeucitinib in plaque psoriasis and outlined plans to file a U.S. FDA New Drug Application this year, highlighting a potential first-in-class,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/what-alumis-almss-envudeucitinib-phase-3-data-and-deepening","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/what-alumis-almss-envudeucitinib-phase-3-data-and-deepening","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126741","title":"Alumis Publishes Corporate Deck on Next-Generation TYK2 Inhibitors for Immune-Mediated Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126741","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126741?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:07","pubTimestamp":1786738077,"startTime":"0","endTime":"0","summary":"Alumis publishes corporate deck on next-generation TYK2 inhibitors for immune-mediated diseasesAlumis highlighted Phase 3 psoriasis efficacy for envudeucitinib, citing Week 24 PASI 100 of 41% in ONWAR","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2KXKqr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659112583","title":"Alumis Price Target Maintained with a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2659112583","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659112583?lang=en_us&edition=fundamental","pubTime":"2026-08-15 01:36","pubTimestamp":1786728960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659992141","title":"Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659992141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659992141?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:40","pubTimestamp":1786711234,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alumis-inc-alms-cabaletta-bio-caba-and-capricor-therapeutics-capr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alumis-inc-alms-cabaletta-bio-caba-and-capricor-therapeutics-capr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","CAPR","BK4588","LU0029874061.USD","LABU","XBI","HCSG","BK4007","BK4139","BK4581","BK4585","LU0128526141.USD","XLV","BK4137","CABA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659149406","title":"Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659149406","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659149406?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:17","pubTimestamp":1786709870,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yatin Suneja from Guggenheim reiterated a Buy rating on Alumis Inc., with a price target of $34.00. The company’s s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659816019","title":"Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659816019","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659816019?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:59","pubTimestamp":1786654767,"startTime":"0","endTime":"0","summary":"Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.71) by 56.34 percent. This is a 12.6 percent increase over losses of $(1.27) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61196225/alumis-q2-eps-1-11-misses-0-71-estimate-sales-1-662m-miss-3-468m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659975160","title":"Alumis Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659975160","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659975160?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:57","pubTimestamp":1786654665,"startTime":"0","endTime":"0","summary":"Alumis Inc. reports results for the quarter ended June 30 - Earnings SummaryAlumis Inc.ALMS.OQreported a quarterly adjusted loss of 79 cents per share for the quarter ended June 30, higher than the sa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A27H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659164039","title":"Alumis Q2 FY26 Net Loss Widens to $142.22 Million; Revenue Falls 37.65% to $1.66 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659164039","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659164039?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651290,"startTime":"0","endTime":"0","summary":"Alumis Q2 FY26 net loss widens to $142.22 million; revenue falls 37.65% to $1.66 millionAlumis posted a net loss of $142.2 million for Q2 2026, swinging from net income of $59.3 million a year earlier","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL8CQkwM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4007","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","BCDF","IE00BN0W2W23.USD","SG9999014039.USD","LU2210150020.SGD","BK4588","ALMS","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167954","title":"Alumis - to Initiate Phase 2 Trial for A-005 in Parkinson's Disease in 1H 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167954?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651261,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA697Z2D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167672","title":"Alumis - on Track to Submit Nda for Envudeucitinib in Pso to FDA in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167672?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651261,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA697Z2D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659640971","title":"Press Release: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2659640971","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659640971?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651260,"startTime":"0","endTime":"0","summary":"that 75% and 54% of patients achieved PASI 90 and PASI 100, respectively,after up to 48 weeks of continuous envudeucitinib treatment , with. envudeucitinib well tolerated and a safety profile consistent with. -- Alumis remains on track to submit its New Drug Application to FDA for. envudeucitinib in PsO in the fourth quarter of 2026.-- Alumis plans to present additional long-term envudeucitinib data at","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SLE","BK4077","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659652481","title":"Alumis Inc. (ALMS) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2659652481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659652481?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:35","pubTimestamp":1786635345,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Alumis Inc., with a price target of $44.00. According...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alumis-inc-alms-receives-a-rating-update-from-a-top-analyst-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alumis-inc-alms-receives-a-rating-update-from-a-top-analyst-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658957988","title":"Alumis reports strong Phase 3 data for envudeucitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2658957988","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658957988?lang=en_us&edition=fundamental","pubTime":"2026-08-11 06:15","pubTimestamp":1786400134,"startTime":"0","endTime":"0","summary":"Alumis Inc. ( ($ALMS) ) has issued an announcement. On August 10, 2026, Alumis reported topline long-term extension data from its Phase 3 ONWARD3 s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alumis-reports-strong-phase-3-data-for-envudeucitinib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alumis-reports-strong-phase-3-data-for-envudeucitinib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959748","title":"Alumis - Envudeucitinib Shows Consistent Safety Profile with no New Safety Signals in Onward3","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959748?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658959712","title":"Alumis - Topline Data from Lumus Phase 2B Trial in Lupus Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658959712","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658959712?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658790959","title":"Alumis - to Submit Nda to FDA for Envudeucitinib in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658790959","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658790959?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658597679","title":"Alumis - 75% of Patients Achieve Pasi 90, 54% Achieve Pasi 100 After 48 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2658597679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658597679?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:20","pubTimestamp":1786393214,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658594439","title":"Alumis Says Envudeucitinib Hits 54% PASI 100 at 48 Weeks in Onward3 Plaque Psoriasis Extension Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2658594439","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658594439?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:16","pubTimestamp":1786393015,"startTime":"0","endTime":"0","summary":"Alumis says envudeucitinib hits 54% PASI 100 at 48 weeks in ONWARD3 plaque psoriasis extension studyAlumis reported topline long-term extension results for envudeucitinib in moderate-to-severe plaque ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLbXgvJt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952654","title":"Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952654","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658952654?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392300,"startTime":"0","endTime":"0","summary":"– ONWARD3 data show 54% of patients reached complete skin clearance (PASI 100) after 48 weeks of continuous envudeucitinib treatment –  – Favorable long-term safety and tolerability profile remained c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/10/3342219/0/en/envudeucitinib-long-term-data-positioned-to-set-a-new-standard-for-plaque-psoriasis-treatment-delivering-highest-reported-pasi-100-skin-clearance-among-oral-therapies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","BK4007","ALMS","SMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656320725","title":"Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2656320725","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656320725?lang=en_us&edition=fundamental","pubTime":"2026-08-03 18:15","pubTimestamp":1785752131,"startTime":"0","endTime":"0","summary":"Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Hold rating on Alumis Inc., retaining the price target of $25.00. Mitchell Kapoor has given...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alumis-competitive-pressures-and-dosing-drawbacks-support-hold-rating-and-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alumis-competitive-pressures-and-dosing-drawbacks-support-hold-rating-and-unchanged-25-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":98,"code":"91000000","status":"200"}]}}